Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Subspecialties

Claudin 18.2: a new therapeutic target: What are the implications for cytopathologists?

May 2025—Claudin 18.2 (CLDN18.2), an isoform of claudin-18, is a transmembrane tight junction protein essential for maintaining barrier function and cell polarity in normal gastric and pancreatic epithelium. In malignant epithelial cells, the loss of polarity exposes the CLDN18.2 epitope, leading to its increased expression in gastric and pancreatic adenocarcinomas. CLDN18.2 has drawn attention as a therapeutic target, particularly with the development of the monoclonal IgG antibody zolbetuximab (Vyloy, Astellas Pharma). Zolbetuximab exerts its antitumor effects via both antibody-dependent and complement-mediated cytotoxicity and has demonstrated significantly improved progression-free and overall survival when combined with standard chemotherapy in two pivotal phase three clinical trials (SPOTLIGHT and GLOW). These data validated CLDN18.2 as a promising target in advanced, HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma.

The future of clinical laboratories in value-based care—Is this our tomorrow to lose?

April 2025—Many look to CAP TODAY to be a central disseminator of news, opinion, and other important information, and it has in the past filled that role in response to others’ requests. One such recent request is that of the Clinical Lab 2.0 movement, established in 2017 by the Project Santa Fe Foundation. We present here, for CAP TODAY readers, the Clinical Lab 2.0 movement’s position paper.

FIGO endometrial cancer staging, 2 years in

April 2025—Seen through the lens of metaphor, cancer staging is traffic control. Identify the biological crash, so to speak, and its severity; direct and redirect therapy; and try, ultimately, to unsnarl persistently risky crossings. That’s the sunny ideal. But efforts to improve traffic flow can also give rise to strong reactions, usually in words (if not a chorus of honking horns). Such is the case with the updated International Federation of Gynecology and Obstetrics staging system for endometrial cancer. FIGO 2023, by nearly all accounts, differs sharply from what had come before, incorporating molecular alterations, lymphovascular invasion, and tumor type and grade. Nearly two years later, it has yet to merge seamlessly into practice. “It definitely is controversial,” says Ekene Okoye, MD, associate professor of clinical pathology and genomic medicine, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College.

Not to be overlooked: lab administrative skill

April 2025—The transition from pathology training to practice is not just about diagnostic skill and confidence in that skill but also laboratory administrative duties, with experience in the latter harder to gain as a trainee.

Myeloid malignancies in WHO-HEM5 and ICC

April 2025—Speakers in a CAP24 session last fall spotlighted the differences between the WHO fifth edition of hematolymphoid tumors and the International Consensus Classification and set forth a framework for how to approach myeloid malignancy cases.

More gonorrhea resistance testing needed

April 2025—For Neisseria gonorrhoeae, the pipeline of antibiotics is running dry, and antimicrobial resistance is a global threat. “It’s just a matter of when it’s going to happen,” says Olusegun O. Soge, PhD, MSc, associate professor of global health and of medicine and adjunct associate professor of laboratory medicine and pathology at the University of Washington.

At the VHA, a mass-scale move to digital pathology

April 2025—Unprecedented moves with a lot of moving parts is how Jessica Wang-Rodriguez, MD, of the Veterans Health Administration describes a transition to digital pathology the size of the VHA’s. It’s a mission that has become necessary, Dr. Wang-Rodriguez says of the large-scale digital pathology transformation. She is executive director of the VHA National Pathology and Laboratory Medicine Program Office, Washington, DC, and professor of pathology at the University of California, San Diego.

Diagnostics, access, therapies on minds ahead of ASCO

April 2025—Rebecca Previs, MD, MS, gynecologic oncologist and director of medical affairs at Labcorp, captures the vibe ahead of the ASCO conference next month in Chicago in just a few words. “It’s exciting,” she says. “This is unprecedented territory.” With the field undergoing “a major shift toward biology-driven rather than tissue-of-origin-driven oncology treatment,” Dr. Previs is far from the only industry representative who is optimistic about the future—though the many challenges ahead temper that excitement.

Liquid biopsy’s promise and complexities

March 2025—Like an inspired Adam in the Garden of Eden, molecular experts have been busy with the naming process as it applies to liquid biopsy. It’s lost to the myths of time whether Adam revised his nomenclature, but pathologists and other experts are eager to identify new assays as they push this field forward, from circulating cell-free DNA to circulating tumor DNA to circulating tumor RNA. Soon another assay, one that combines ctDNA and ctRNA, could begin to make its mark as well, says Keyur P. Patel, MD, PhD, medical director of the molecular diagnostics laboratory, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center. He and his colleagues plan to launch an assay to look for circulating total nucleic acid. “DNA plus RNA equals TNA—that’s the mathematical equation,” jokes Dr. Patel, who is also professor, Department of Hematopathology, Division of Pathology and Laboratory Medicine. And like that first zookeeper, there’s even an actual beast for experts to name.

Interpreting patient PEth post-transfusion

March 2025—Theresa Kinard, MD, knew little about phosphatidylethanol (PEth), a blood-based biomarker of alcohol use, when she noticed that patients who adamantly denied drinking were testing positive in their liver pretransplant evaluations.

MARKETPLACE

TRENDING